jama tirzepatide Potential rare vision complications tied to blockbuster GLP-1s Continued tirzepatide treatment enhances weight

2018 Diabetes Ther

In several studies, it has been observed that the group given NAC supplementation had decreased hyperphosphorylation of Tau in the hippocampus and medial prefrontal cortex

Figure 2 5 Clinical research progress and safety evaluation 5.1 Clinical efficacy studies Tirzepatide, a novel dual GLP-1 and GIP receptor agonist, has demonstrated remarkable efficacy in the management of type 2 diabetes and obesity, as evidenced by multiple high-quality clinical trials (43, 44)

Ask whether your doctor thinks genetic testing could help optimize your treatment plan before starting or early in your therapy